Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Terry A DayKeisuke ShiraiPaul E O'BrienMaria Gisele MatheusKristina GodwinAmit J SoodAnvesh KompelliJulie A VickDaniel MartinLynn Vitale-CrossJuan Luis Callejas-VarelaZhiyong WangXingyu WuOlivier HarismendyNapoleone FerraraScott M LippmanCarter Van WaesEva SzaboJ Silvio GutkindPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Rapamycin treatment was well tolerated, reduced mTOR signaling and tumor growth, and resulted in significant clinical responses despite the brief treatment duration, thus supporting the potential role of mTOR inhibitors in treatment regimens for HNSCC.